[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT03331198":3,"trial-entities:NCT03331198":737,"trial-summary:NCT03331198":745},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":28,"interventions":31,"primary_outcomes":50,"secondary_outcomes":80,"sex":195,"minimum_age":196,"maximum_age":17,"healthy_volunteers":197,"eligibility_criteria":198,"std_ages":232,"locations":235,"central_contacts":711,"overall_officials":712,"references":716,"see_also_links":730},"NCT03331198","017004","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","An Open-Label, Phase 1\u002F2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)","ACTIVE_NOT_RECRUITING","2027-11-26","2026-07","2026-07-06","2017-11-27","Juno Therapeutics, a Subsidiary of Celgene","INDUSTRY",true,"This is a Phase 1\u002F2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.",null,[19,20],"Leukemia, Lymphocytic, Chronic, B-Cell","Lymphoma, Small Lymphocytic",[22],"TRANSCEND_CLL_004","INTERVENTIONAL","TREATMENT",[26,27],"PHASE1","PHASE2",{"count":29,"type":30},320,"ESTIMATED",[32,40,45],{"type":33,"name":34,"description":35,"armGroupLabels":36},"BIOLOGICAL","JCAR017 (lisocabtagene maraleucel)","Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.",[37,38,39],"Phase 1 JCAR017 monotherapy","Phase 2 JCAR017 Double-Exposed Monotherapy Expansion (DEME)","Phase 2 JCAR017 monotherapy",{"type":33,"name":41,"description":42,"armGroupLabels":43},"JCAR017 (lisocabtagene maraleucel) + ibrutinib","Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.",[44],"Phase 1 JCAR017 + ibrutinib",{"type":33,"name":46,"description":47,"armGroupLabels":48},"JCAR017 (lisocabtagene maraleucel) + venetoclax","Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.",[49],"Phase 1 JCAR017 + venetoclax",[51,55,58,60,62,66,68,70,73,76],{"measure":52,"description":53,"timeFrame":54},"Phase 1 JCAR017 monotherapy arm: adverse events","Proportion of subjects experiencing adverse events","Up to 48 months post treatment",{"measure":56,"description":57,"timeFrame":54},"Phase 1 JCAR017 monotherapy arm: laboratory abnormalities","Proportion of subjects experiencing laboratory abnormalities",{"measure":59,"description":53,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events",{"measure":61,"description":57,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities",{"measure":63,"description":64,"timeFrame":65},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm","Proportion of subjects who have CR after treatment with JCAR017 + ibrutinib using iwCLL 2018 guidelines","Through post treatment up to Month 48",{"measure":67,"description":53,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse events",{"measure":69,"description":57,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalities",{"measure":71,"description":72,"timeFrame":65},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm","Proportion of subjects who have CR after treatment with JCAR017 + venetoclax using iwCLL 2018 guidelines",{"measure":74,"description":75,"timeFrame":65},"Phase 2 JCAR017 monotherapy expansion arm","Proportion of subjects who have CR after treatment with JCAR017 using iwCLL 2018 guidelines",{"measure":77,"description":78,"timeFrame":79},"Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)","ORR defined as the rate of complete response\u002Fremission (CR) \\[including complete response\u002Fremission with incomplete marrow recovery (Cri)\\] plus PR \\[including nodular partial response (nPR)\\] based on Independent Review Committee (IRC) assessment using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines","Up to approximately 24 months",[81,83,85,88,91,93,96,99,102,105,108,111,114,116,119,121,123,125,127,129,131,133,135,137,139,141,143,145,147,149,151,153,155,157,160,163,166,169,171,173,175,177,180,183,186,188,191,193],{"measure":82,"description":53,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: adverse events",{"measure":84,"description":57,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: laboratory abnormalities",{"measure":86,"description":87,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: ORR","Defined as the rate of CR (including CRi)",{"measure":89,"description":90,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD negative response rate in peripheral blood","Proportion of subjects who achieve MRD CR",{"measure":92,"description":90,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD-negative CR rate in peripheral blood",{"measure":94,"description":95,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of response (DOR)","Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause",{"measure":97,"description":98,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of complete response (DoCR)","Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause",{"measure":100,"description":101,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to response (TTR)","Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR",{"measure":103,"description":104,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to complete response (TTCR)","Defined as the interval from JCAR017 infusion to the first documentation of CR",{"measure":106,"description":107,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: PFS","Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause",{"measure":109,"description":110,"timeFrame":54},"Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: OS","Defined as the time from JCAR017 infusion to the date of death due to any cause",{"measure":112,"description":113,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: adverse events","Proportion of subject experiencing adverse events",{"measure":115,"description":57,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: lab abnormalities",{"measure":117,"description":87,"timeFrame":118},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: ORR","Through post treatment Day 90",{"measure":120,"description":90,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: MRD-negative response rate in peripheral blood",{"measure":122,"description":90,"timeFrame":118},"Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: MRD-negative CR rate in peripheral blood",{"measure":124,"description":95,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of response (DOR)",{"measure":126,"description":98,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of complete response (DoCR)",{"measure":128,"description":101,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to response (TTR)",{"measure":130,"description":104,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to complete response (TTCR)",{"measure":132,"description":107,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: PFS",{"measure":134,"description":110,"timeFrame":54},"Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: OS",{"measure":136,"description":53,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: adverse events",{"measure":138,"description":57,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: laboratory abnormalities",{"measure":140,"description":87,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: ORR",{"measure":142,"description":90,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: MRD negative response rate in peripheral blood",{"measure":144,"description":90,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: MRD-negative CR rate in peripheral blood",{"measure":146,"description":95,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: Duration of response (DOR)",{"measure":148,"description":98,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: Duration of complete response (DoCR)",{"measure":150,"description":101,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: Time to response (TTR)",{"measure":152,"description":104,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: Time to complete response (TTCR)",{"measure":154,"description":107,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: PFS",{"measure":156,"description":110,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: OS",{"measure":158,"description":159,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: Health-related quality of life (HRQoL) questionnaire","Change from baseline in HRQoL assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30",{"measure":161,"description":162,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: HRQoL questionnaire","Change from baseline in HRQoL assessed using the EORTC chronic lymphocytic leukemia (CLL)-specific module QLQ-CLL-17",{"measure":164,"description":165,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: Health economics and outcomes research (HEOR) questionnaire","Change from baseline in measurement of health utility values using EuroQol instrument EQ-5D-5L",{"measure":167,"description":168,"timeFrame":54},"Phase 2 JCAR017 Monotherapy Expansion Arm: HEOR questionnaire","Proportion of participants with intensive care unit (ICU) inpatient days",{"measure":167,"description":170,"timeFrame":54},"Proportion of participants with non-ICU inpatient days",{"measure":172,"description":53,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: adverse events",{"measure":174,"description":57,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: laboratory abnormalities",{"measure":176,"description":95,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Duration of response (DOR)",{"measure":178,"description":179,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: CR rate","Defined as the rate of CR (including CRi) based on IRC assessment using iwCLL 2018 guidelines",{"measure":181,"description":182,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: MRD-negative response rate in peripheral blood","Proportion of subjects who achieve MRD negative status",{"measure":184,"description":185,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: MRD-negative CR rate in peripheral blood","Proportion of subjects who achieve MRD-negative CR",{"measure":187,"description":101,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Time to response (TTR)",{"measure":189,"description":190,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Time to complete response (TTCR)","Define as the interval from JCAR017 infusion to the first documentation of CR",{"measure":192,"description":107,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Progression free survival (PFS)",{"measure":194,"description":110,"timeFrame":79},"Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Overall Survival (OS)","ALL","18 Years",false,{"inclusion":199,"exclusion":213,"raw_text":231},[200,201,202,203,204,205,206,207,208,209,210,211,212],"Diagnosis of:","Subjects (other than those in the ibrutinib + JCAR017 combination therapy and DEME cohort) must have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy.","Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows:","Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:","Eastern Cooperative Oncology Group performance status of ≤ 1","Assessed by the Investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy","Adequate organ function, defined as:","Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.","If prior CD19-targeted therapy has been administered, subject must have CD19-positive disease confirmed by immunohistochemistry or flow cytometry since completing the prior CD19-targeted therapy.","Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and have received prior therapy with venetoclax","Subjects in venetoclax + JCAR017 combination cohort must:","subjects in the venetoclax + JCAR017 combination must have hemoglobin \\>=9 g\u002FdL, absolute neutrophil count \\>=500mm3 and platelets\\>= 75,000\u002Fmm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow","must have diagnosis of CLL or SLL with an indication for treatment based on the investigator's opinion and measurable disease (any of the following measurable lymph nodes ≥1.5 cm in the greatest transverse diameter and\u002For hepatomegaly or splenomegaly) and demonstration of CLL cells in the peripheral blood by flow cytometry",[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230],"Subjects with known active central nervous system (CNS) involvement by malignancy. Those with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging.","History of another primary malignancy that has not been in remission for at least 2 years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer, completely resected stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.)","Subjects with Richter's transformation","Prior treatment with any gene therapy product","Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV) infection","Systemic fungal, bacterial, viral, or other infection that is not controlled","Presence of acute or extensive chronic graft versus host disease (GVHD)","History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease","History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or psychosis","Pregnant or nursing (lactating) women","Use of any of the following medications or treatments within the noted time prior to leukapheresis:","Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocol","Progressive vascular tumor invasion, thrombosis, or embolism","Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation","Use of any of the following medications or treatments within the noted time prior to leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis experimental agents, including off-label use of approved drugs, within 4 weeks prior to leukapheresis.","Venous thrombosis or embolism requiring treatment but not managed on a stable regimen of anticoagulation","For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant treatment with CYP3A moderate\u002Fstrong inducers or moderate\u002Fstrong inhibitors which cannot be discontinued","Inclusion Criteria:\n\n* Diagnosis of:\n\n  1. CLL with an indication for treatment based on the Investigator's opinion and measurable disease, or\n  2. SLL (lymphadenopathy and\u002For splenomegaly and \\\u003C 5×10\\^9 CD19+ CD5+ clonal B lymphocytes\u002FL \\[\\\u003C 5000\u002FµL\\] in the peripheral blood at diagnosis with measurable disease that is biopsy-proven SLL)\n* Subjects (other than those in the ibrutinib + JCAR017 combination therapy and DEME cohort) must have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy.\n* Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows:\n\n  1. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and high-risk features must have failed at least 2 lines of prior therapy.\n  2. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and standard-risk features must have failed at least 3 lines of prior therapy.\n  3. DEME cohort ONLY: Subjects with relapsed or refractory CLL or SLL, irrespective of cytogenetic risk features, must have received at least 2 lines of prior therapy including a BTKi and a BCL2i.\n* Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:\n\n  1. be receiving ibrutinib and progressing at the time of study enrollment\n  2. be receiving ibrutinib for at least 6 months with a response less than complete response\u002Fremission (CR) and have high-risk features as defined in inclusion criterion 5a\n  3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without progression on ibrutinib\n  4. have previously received ibrutinib and have no contraindications to restarting ibrutinib\n* Eastern Cooperative Oncology Group performance status of ≤ 1\n* Assessed by the Investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy\n* Adequate organ function, defined as:\n\n  1. Serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) OR calculated creatinine clearance \\> 30 mL\u002Fmin\n  2. Alanine aminotransferase ≤ 5 × ULN and total bilirubin \\\u003C 2.0 mg\u002FdL (or \\\u003C 3.0 mg\u002FdL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)\n  3. Adequate pulmonary function, defined as ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air\n  4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility\n* Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.\n* If prior CD19-targeted therapy has been administered, subject must have CD19-positive disease confirmed by immunohistochemistry or flow cytometry since completing the prior CD19-targeted therapy.\n* Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and have received prior therapy with venetoclax\n* Subjects in venetoclax + JCAR017 combination cohort must:\n\n  1. have failed at least 1 prior line of therapy, including failed BTKi therapy or have been deemed ineligible to receive BTKi\n  2. be venetoclax naive (required for dose expansion) or\n  3. if prior venetoclax (only for dose escalation)\n  4. have no contraindictions to re-initiation of venetoclax based on prior intolerance and have had at least 6 months elapsed since the last dose of venetoclax, if either, best response was stable disease, or subject experienced disease progression on venetoclax, or within 6 months of venetoclax discontinuation\n* subjects in the venetoclax + JCAR017 combination must have hemoglobin \\>=9 g\u002FdL, absolute neutrophil count \\>=500mm3 and platelets\\>= 75,000\u002Fmm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow\n* must have diagnosis of CLL or SLL with an indication for treatment based on the investigator's opinion and measurable disease (any of the following measurable lymph nodes ≥1.5 cm in the greatest transverse diameter and\u002For hepatomegaly or splenomegaly) and demonstration of CLL cells in the peripheral blood by flow cytometry\n\nExclusion Criteria:\n\n* Subjects with known active central nervous system (CNS) involvement by malignancy. Those with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging.\n* History of another primary malignancy that has not been in remission for at least 2 years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer, completely resected stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.)\n* Subjects with Richter's transformation\n* Prior treatment with any gene therapy product\n* Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV) infection\n* Systemic fungal, bacterial, viral, or other infection that is not controlled\n* Presence of acute or extensive chronic graft versus host disease (GVHD)\n* History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease\n* History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or psychosis\n* Pregnant or nursing (lactating) women\n* Use of any of the following medications or treatments within the noted time prior to leukapheresis:\n\n  1. Alemtuzumab within 6 months prior to leukapheresis\n  2. Allogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresis\n  3. Cladribine within 3 months prior to leukapheresis\n  4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis\n  5. Radiation including large bone marrow fields such as sternum or pelvis within 6 weeks prior to leukapheresis\n  6. Fludarabine within 4 weeks prior to leukapheresis\n  7. GVHD therapies such as calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive antibodies (such as anti-tumor necrosis factor-α \\[TNFα\\], anti-interleukin-6 \\[IL-6\\], or anti-interleukin-6 receptor \\[IL 6R\\]) within 4 weeks prior to leukapheresis\n  8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2 weeks prior to leukapheresis\n  9. Therapeutic doses of corticosteroids (defined as \\> 20 mg\u002Fday prednisone or equivalent) within 7 days prior to leukapheresis\n  10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis\n  11. Venetoclax within 4 days prior to leukapheresis\n  12. Idelalisib or duvelisib within 2 days prior to leukapheresis\n  13. Lenalidomide or covalent and non-covalent BTKi within 1 day prior to leukapheresis\n  14. Experimental agents, including off-label use of approved drugs (with the exception of acalabrutinib which may be continued up to the day before leukapheresis), within 4 weeks prior to leukapheresis unless progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis\n* Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocol\n* Progressive vascular tumor invasion, thrombosis, or embolism\n* Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation\n* Use of any of the following medications or treatments within the noted time prior to leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis experimental agents, including off-label use of approved drugs, within 4 weeks prior to leukapheresis.\n* Venous thrombosis or embolism requiring treatment but not managed on a stable regimen of anticoagulation\n* For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant treatment with CYP3A moderate\u002Fstrong inducers or moderate\u002Fstrong inhibitors which cannot be discontinued",[233,234],"ADULT","OLDER_ADULT",[236,245,248,256,259,267,270,277,280,287,290,297,300,308,316,319,327,330,338,342,345,353,356,360,363,371,379,387,395,403,406,410,413,421,425,432,435,439,447,449,457,460,468,475,482,486,493,500,503,510,514,518,525,533,540,544,551,559,563,570,578,581,589,597,600,604,607,614,617,625,632,640,644,647,651,658,661,669,672,680,688,691,699,702],{"facility":237,"city":238,"state":239,"zip":240,"country":241,"geoPoint":242},"Local Institution - 0006","Birmingham","Alabama","35294","United States",{"lat":243,"lon":244},33.52066,-86.80249,{"facility":246,"city":238,"state":239,"zip":240,"country":241,"geoPoint":247},"University of Alabama at Birmingham",{"lat":243,"lon":244},{"facility":249,"city":250,"state":251,"zip":252,"country":241,"geoPoint":253},"Banner MD Anderson Cancer Center","Gilbert","Arizona","85234",{"lat":254,"lon":255},33.35283,-111.78903,{"facility":257,"city":250,"state":251,"zip":252,"country":241,"geoPoint":258},"Local Institution - 0043",{"lat":254,"lon":255},{"facility":260,"city":261,"state":262,"zip":263,"country":241,"geoPoint":264},"City of Hope","Duarte","California","91010",{"lat":265,"lon":266},34.13945,-117.97729,{"facility":268,"city":261,"state":262,"zip":263,"country":241,"geoPoint":269},"Local Institution - 0007",{"lat":265,"lon":266},{"facility":271,"city":272,"state":262,"zip":273,"country":241,"geoPoint":274},"Local Institution - 0025","La Jolla","92093",{"lat":275,"lon":276},32.84727,-117.2742,{"facility":278,"city":272,"state":262,"zip":273,"country":241,"geoPoint":279},"UC San Diego Moores Cancer Center",{"lat":275,"lon":276},{"facility":281,"city":282,"state":262,"zip":283,"country":241,"geoPoint":284},"Local Institution - 0059","Los Angeles","90095",{"lat":285,"lon":286},34.05223,-118.24368,{"facility":288,"city":282,"state":262,"zip":283,"country":241,"geoPoint":289},"University of California, Los Angeles",{"lat":285,"lon":286},{"facility":291,"city":292,"state":262,"zip":293,"country":241,"geoPoint":294},"Local Institution - 0010","San Francisco","94143",{"lat":295,"lon":296},37.77493,-122.41942,{"facility":298,"city":292,"state":262,"zip":293,"country":241,"geoPoint":299},"University of California, San Francisco",{"lat":295,"lon":296},{"facility":301,"city":302,"state":303,"zip":304,"country":241,"geoPoint":305},"Local Institution - 0111","Denver","Colorado","80218",{"lat":306,"lon":307},39.73915,-104.9847,{"facility":309,"city":310,"state":311,"zip":312,"country":241,"geoPoint":313},"Georgetown University Medical Center","Washington D.C.","District of Columbia","20007",{"lat":314,"lon":315},38.89511,-77.03637,{"facility":317,"city":310,"state":311,"zip":312,"country":241,"geoPoint":318},"Local Institution - 0085",{"lat":314,"lon":315},{"facility":320,"city":321,"state":322,"zip":323,"country":241,"geoPoint":324},"Local Institution - 0080","Jacksonville","Florida","32224",{"lat":325,"lon":326},30.33218,-81.65565,{"facility":328,"city":321,"state":322,"zip":323,"country":241,"geoPoint":329},"Mayo Clinic",{"lat":325,"lon":326},{"facility":331,"city":332,"state":333,"zip":334,"country":241,"geoPoint":335},"Local Institution - 0104","Atlanta","Georgia","30322",{"lat":336,"lon":337},33.749,-84.38798,{"facility":339,"city":332,"state":333,"zip":340,"country":241,"geoPoint":341},"Local Institution - 0019","30342",{"lat":336,"lon":337},{"facility":343,"city":332,"state":333,"zip":340,"country":241,"geoPoint":344},"The Blood and Marrow Transplant Group of Georgia (BMTGA)",{"lat":336,"lon":337},{"facility":346,"city":347,"state":348,"zip":349,"country":241,"geoPoint":350},"Local Institution - 0003","Chicago","Illinois","60611",{"lat":351,"lon":352},41.85003,-87.65005,{"facility":354,"city":347,"state":348,"zip":349,"country":241,"geoPoint":355},"Northwestern University",{"lat":351,"lon":352},{"facility":357,"city":347,"state":348,"zip":358,"country":241,"geoPoint":359},"Local Institution - 0016","60637",{"lat":351,"lon":352},{"facility":361,"city":347,"state":348,"zip":358,"country":241,"geoPoint":362},"University of Chicago Medical Center",{"lat":351,"lon":352},{"facility":364,"city":365,"state":366,"zip":367,"country":241,"geoPoint":368},"Local Institution - 0105","Indianapolis","Indiana","46237",{"lat":369,"lon":370},39.76838,-86.15804,{"facility":372,"city":373,"state":374,"zip":375,"country":241,"geoPoint":376},"Local Institution - 0107","Wichita","Kansas","67124",{"lat":377,"lon":378},37.69224,-97.33754,{"facility":380,"city":381,"state":382,"zip":383,"country":241,"geoPoint":384},"Local Institution - 0064","Louisville","Kentucky","40202",{"lat":385,"lon":386},38.25424,-85.75941,{"facility":388,"city":389,"state":390,"zip":391,"country":241,"geoPoint":392},"Local Institution - 0027","New Orleans","Louisiana","70112",{"lat":393,"lon":394},29.95465,-90.07507,{"facility":396,"city":397,"state":398,"zip":399,"country":241,"geoPoint":400},"Local Institution - 0005","Boston","Massachusetts","02114",{"lat":401,"lon":402},42.35843,-71.05977,{"facility":404,"city":397,"state":398,"zip":399,"country":241,"geoPoint":405},"Massachusetts General Hospital",{"lat":401,"lon":402},{"facility":407,"city":397,"state":398,"zip":408,"country":241,"geoPoint":409},"Beth Israel Deaconess Medical Center","02215",{"lat":401,"lon":402},{"facility":411,"city":397,"state":398,"zip":408,"country":241,"geoPoint":412},"Local Institution - 0015",{"lat":401,"lon":402},{"facility":414,"city":415,"state":416,"zip":417,"country":241,"geoPoint":418},"University of Michigan Comprehensive Cancer Center","Ann Arbor","Michigan","48109-5362",{"lat":419,"lon":420},42.27756,-83.74088,{"facility":422,"city":415,"state":416,"zip":423,"country":241,"geoPoint":424},"Local Institution - 0084","48109",{"lat":419,"lon":420},{"facility":426,"city":427,"state":416,"zip":428,"country":241,"geoPoint":429},"Barbara Ann Karmanos Cancer Institute","Detroit","48201",{"lat":430,"lon":431},42.33143,-83.04575,{"facility":433,"city":427,"state":416,"zip":428,"country":241,"geoPoint":434},"Local Institution - 0062",{"lat":430,"lon":431},{"facility":436,"city":427,"state":416,"zip":437,"country":241,"geoPoint":438},"Local Institution - 0109","48202",{"lat":430,"lon":431},{"facility":440,"city":441,"state":442,"zip":443,"country":241,"geoPoint":444},"Local Institution - 0054","Rochester","Minnesota","55905",{"lat":445,"lon":446},44.02163,-92.4699,{"facility":328,"city":441,"state":442,"zip":443,"country":241,"geoPoint":448},{"lat":445,"lon":446},{"facility":450,"city":451,"state":452,"zip":453,"country":241,"geoPoint":454},"Local Institution - 0008","Omaha","Nebraska","68198",{"lat":455,"lon":456},41.25626,-95.94043,{"facility":458,"city":451,"state":452,"zip":453,"country":241,"geoPoint":459},"University of Nebraska Medical Center",{"lat":455,"lon":456},{"facility":461,"city":462,"state":463,"zip":464,"country":241,"geoPoint":465},"Local Institution - 0001","Basking Ridge","New Jersey","07920",{"lat":466,"lon":467},40.70621,-74.54932,{"facility":469,"city":470,"state":463,"zip":471,"country":241,"geoPoint":472},"Local Institution - 0114","Edison","08820",{"lat":473,"lon":474},40.51872,-74.4121,{"facility":476,"city":477,"state":463,"zip":478,"country":241,"geoPoint":479},"Local Institution - 0038","Hackensack","07601-2191",{"lat":480,"lon":481},40.88593,-74.04347,{"facility":483,"city":477,"state":463,"zip":484,"country":241,"geoPoint":485},"Hackensack University Medical Center","07601",{"lat":480,"lon":481},{"facility":487,"city":488,"state":463,"zip":489,"country":241,"geoPoint":490},"Local Institution - 0106","Morristown","07960",{"lat":491,"lon":492},40.79677,-74.48154,{"facility":494,"city":495,"state":463,"zip":496,"country":241,"geoPoint":497},"Local Institution - 0077","New Brunswick","08903",{"lat":498,"lon":499},40.48622,-74.45182,{"facility":501,"city":495,"state":463,"zip":496,"country":241,"geoPoint":502},"Rutgers Cancer Institute of New Jersey",{"lat":498,"lon":499},{"facility":504,"city":505,"state":505,"zip":506,"country":241,"geoPoint":507},"Local Institution - 0035","New York","10021",{"lat":508,"lon":509},40.71427,-74.00597,{"facility":511,"city":505,"state":505,"zip":512,"country":241,"geoPoint":513},"Local Institution - 0026","10032",{"lat":508,"lon":509},{"facility":515,"city":505,"state":505,"zip":516,"country":241,"geoPoint":517},"Weill Cornell Medical College","10065",{"lat":508,"lon":509},{"facility":519,"city":520,"state":505,"zip":521,"country":241,"geoPoint":522},"Local Institution - 0089","Stony Brook","11794-8160",{"lat":523,"lon":524},40.92565,-73.14094,{"facility":526,"city":527,"state":528,"zip":529,"country":241,"geoPoint":530},"Local Institution - 0120","Charlotte","North Carolina","28204",{"lat":531,"lon":532},35.22709,-80.84313,{"facility":534,"city":535,"state":528,"zip":536,"country":241,"geoPoint":537},"Local Institution - 0030","Durham","27705",{"lat":538,"lon":539},35.99403,-78.89862,{"facility":541,"city":535,"state":528,"zip":542,"country":241,"geoPoint":543},"Duke University Medical Center","27710",{"lat":538,"lon":539},{"facility":545,"city":546,"state":528,"zip":547,"country":241,"geoPoint":548},"Local Institution - 0118","Winston-Salem","27157",{"lat":549,"lon":550},36.09986,-80.24422,{"facility":552,"city":553,"state":554,"zip":555,"country":241,"geoPoint":556},"University Hospitals Seidman Cancer Center (Case Western)","Cleveland","Ohio","44106-5061",{"lat":557,"lon":558},41.4995,-81.69541,{"facility":560,"city":553,"state":554,"zip":561,"country":241,"geoPoint":562},"Local Institution - 0078","44106",{"lat":557,"lon":558},{"facility":564,"city":565,"state":554,"zip":566,"country":241,"geoPoint":567},"Local Institution - 0031","Columbus","43210",{"lat":568,"lon":569},39.96118,-82.99879,{"facility":571,"city":572,"state":573,"zip":574,"country":241,"geoPoint":575},"Local Institution - 0082","Oklahoma City","Oklahoma","73104",{"lat":576,"lon":577},35.46756,-97.51643,{"facility":579,"city":572,"state":573,"zip":574,"country":241,"geoPoint":580},"University of Oklahoma Health Sciences Center (Stephenson Cancer Center)",{"lat":576,"lon":577},{"facility":582,"city":583,"state":584,"zip":585,"country":241,"geoPoint":586},"Local Institution - 0098","Eugene","Oregon","97401",{"lat":587,"lon":588},44.05207,-123.08675,{"facility":590,"city":591,"state":592,"zip":593,"country":241,"geoPoint":594},"Local Institution - 0088","Philadelphia","Pennsylvania","19104",{"lat":595,"lon":596},39.95238,-75.16362,{"facility":598,"city":591,"state":592,"zip":593,"country":241,"geoPoint":599},"University of Pennsylvania Perelman Center for Advanced Medicine",{"lat":595,"lon":596},{"facility":601,"city":591,"state":592,"zip":602,"country":241,"geoPoint":603},"Local Institution - 0032","19107",{"lat":595,"lon":596},{"facility":605,"city":591,"state":592,"zip":602,"country":241,"geoPoint":606},"Thomas Jefferson University",{"lat":595,"lon":596},{"facility":608,"city":609,"state":592,"zip":610,"country":241,"geoPoint":611},"Local Institution - 0029","Pittsburgh","15232",{"lat":612,"lon":613},40.44062,-79.99589,{"facility":615,"city":609,"state":592,"zip":610,"country":241,"geoPoint":616},"UPMC Hillman Cancer Center",{"lat":612,"lon":613},{"facility":618,"city":619,"state":620,"zip":621,"country":241,"geoPoint":622},"Local Institution - 0117","Chattanooga","Tennessee","37403",{"lat":623,"lon":624},35.04563,-85.30968,{"facility":626,"city":627,"state":620,"zip":628,"country":241,"geoPoint":629},"Local Institution - 0119","Nashville","37203",{"lat":630,"lon":631},36.16589,-86.78444,{"facility":633,"city":634,"state":635,"zip":636,"country":241,"geoPoint":637},"Baylor University Medical Center","Dallas","Texas","75246",{"lat":638,"lon":639},32.78306,-96.80667,{"facility":641,"city":634,"state":635,"zip":642,"country":241,"geoPoint":643},"Local Institution - 0083","75390",{"lat":638,"lon":639},{"facility":645,"city":634,"state":635,"zip":642,"country":241,"geoPoint":646},"University of Texas Southwestern Medical Center",{"lat":638,"lon":639},{"facility":648,"city":634,"state":635,"zip":649,"country":241,"geoPoint":650},"Local Institution - 0079","75426",{"lat":638,"lon":639},{"facility":652,"city":653,"state":635,"zip":654,"country":241,"geoPoint":655},"Local Institution - 0002","Houston","77030",{"lat":656,"lon":657},29.76328,-95.36327,{"facility":659,"city":653,"state":635,"zip":654,"country":241,"geoPoint":660},"The University of Texas MD Anderson Cancer Center",{"lat":656,"lon":657},{"facility":662,"city":663,"state":664,"zip":665,"country":241,"geoPoint":666},"Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"lat":667,"lon":668},40.76078,-111.89105,{"facility":670,"city":663,"state":664,"zip":665,"country":241,"geoPoint":671},"Local Institution - 0028",{"lat":667,"lon":668},{"facility":673,"city":674,"state":675,"zip":676,"country":241,"geoPoint":677},"Local Institution - 0087","Richmond","Virginia","23298",{"lat":678,"lon":679},37.55376,-77.46026,{"facility":681,"city":682,"state":683,"zip":684,"country":241,"geoPoint":685},"Fred Hutchinson Cancer Research Center","Seattle","Washington","98109",{"lat":686,"lon":687},47.60621,-122.33207,{"facility":689,"city":682,"state":683,"zip":684,"country":241,"geoPoint":690},"Local Institution - 0018",{"lat":686,"lon":687},{"facility":692,"city":693,"state":694,"zip":695,"country":241,"geoPoint":696},"Local Institution - 0055","Milwaukee","Wisconsin","53226",{"lat":697,"lon":698},43.0389,-87.90647,{"facility":700,"city":693,"state":694,"zip":695,"country":241,"geoPoint":701},"Medical College of Wisconsin",{"lat":697,"lon":698},{"facility":703,"city":704,"state":705,"zip":706,"country":707,"geoPoint":708},"Local Institution - 0112","Toronto","Ontario","M5G 2C1","Canada",{"lat":709,"lon":710},43.70643,-79.39864,[],[713],{"name":714,"affiliation":714,"role":715},"Bristol-Myers Squibb","STUDY_DIRECTOR",[717,721,724,727],{"pmid":718,"type":719,"citation":720},"42520199","DERIVED","Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB, Ghosh M, Ma S, Schuster SJ, Gergis U, Vose JM, Soumerai JD, van Besien K, Tuazon SA, Perna SK, Ou SS, Ananthakrishnan R, Rane N, Papp E, Ansari S, Thompson EG, Okal A, Peiser L, Chen Y, Sengupta S, Ray PR, Wang J, Siddiqi T. Lisocabtagene maraleucel combined with ibrutinib in R\u002FR CLL or SLL: primary results from TRANSCEND CLL 004. Blood. 2026 Jul 28:blood.2026033565. doi: 10.1182\u002Fblood.2026033565. Online ahead of print.",{"pmid":722,"type":719,"citation":723},"37295445","Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016\u002FS0140-6736(23)01052-8. Epub 2023 Jun 6.",{"pmid":725,"type":719,"citation":726},"35610089","Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. Cytotherapy. 2022 Sep;24(9):962-973. doi: 10.1016\u002Fj.jcyt.2022.03.013. Epub 2022 May 21.",{"pmid":728,"type":719,"citation":729},"34699592","Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\u002Frefractory CLL or SLL. Blood. 2022 Mar 24;139(12):1794-1806. doi: 10.1182\u002Fblood.2021011895.",[731,734],{"label":732,"url":733},"BMS Clinical Trial Information","https:\u002F\u002Fwww.bms.com\u002Fresearchers-and-partners\u002Fclinical-trials-and-research.html",{"label":735,"url":736},"BMS Clinical Trial Patient Recruiting","https:\u002F\u002Fwww.bmsclinicaltrials.com\u002Fus\u002Fen\u002Fclinical-trials\u002FNCT03331198.html",{"nct_id":4,"conditions":738,"biomarkers":741},[739,740],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[742,743,744],"BTK Gene","CD19 Gene","PLCG2 wt Allele",{"nct_id":4,"found":197,"summary":17,"prompt_version":17}]